81 related articles for article (PubMed ID: 9470833)
21. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.
Pohl J; Zuna I; Stremmel W; Rudi J
Chemotherapy; 2001; 47(5):359-65. PubMed ID: 11561139
[TBL] [Abstract][Full Text] [Related]
22. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
[TBL] [Abstract][Full Text] [Related]
26. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma.
Sangro B; Rios R; Bilbao I; Beloqui O; Herrero JI; Quiroga J; Prieto J
Oncology; 2002; 62(4):293-8. PubMed ID: 12138235
[TBL] [Abstract][Full Text] [Related]
29. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
[TBL] [Abstract][Full Text] [Related]
30. [Therapy-related AML(M2) with t(8;21) that developed three years after chemotherapy for hepatocellular carcinoma].
Miyata A; Deguchi S; Fujita M; Kikuchi T; Honda K
Rinsho Ketsueki; 1996 May; 37(5):448-51. PubMed ID: 8691593
[TBL] [Abstract][Full Text] [Related]
31. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Jang JW; Bae SH; Choi JY; Oh HJ; Kim MS; Lee SY; Kim CW; Chang UI; Nam SW; Cha SB; Lee YJ; Chun HJ; Choi BG; Byun JY; Yoon SK
Cancer Chemother Pharmacol; 2007 Jan; 59(1):9-15. PubMed ID: 16614848
[TBL] [Abstract][Full Text] [Related]
32. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma.
Bhattacharya S; Novell JR; Dusheiko GM; Hilson AJ; Dick R; Hobbs KE
Cancer; 1995 Dec; 76(11):2202-10. PubMed ID: 8635022
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival and complete response to adriamycin and etoposide in a case of hepatocellular carcinoma.
Giaccone G; Bonardi G; Leria G; Donadio M; Calciati A
Tumori; 1986 Aug; 72(4):409-11. PubMed ID: 3020753
[TBL] [Abstract][Full Text] [Related]
36. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
Hwang JY; Jang BK; Kwon KM; Chung WJ; Park KS; Cho KB; Hwang JS; Ahn SH; Kim GC; Kim YH; Choi JS; Kwon JH
Korean J Gastroenterol; 2005 Feb; 45(2):118-24. PubMed ID: 15725716
[TBL] [Abstract][Full Text] [Related]
38. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.
Bokemeyer C; Kynast B; Harstrick A; Laage E; Schmoll E; von Wussow P; Schmoll HJ
Cancer Chemother Pharmacol; 1995; 35(4):334-8. PubMed ID: 7828277
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]